RhoDx’s Proprietary NexGenAblerâ„¢ technology is a novel NGS workflow enabling specific, ultrasensitive detection of circulating tumor DNA (ctDNA). NexGenAblerâ„¢ supports early cancer detection and serial measurement of key oncogenic drivers to improve cancer research and drive mechanistic cancer management.